ES2160600T3 - Activacion transcutanea in vivo de agentes fotosensibles en la sangre. - Google Patents

Activacion transcutanea in vivo de agentes fotosensibles en la sangre.

Info

Publication number
ES2160600T3
ES2160600T3 ES93918860T ES93918860T ES2160600T3 ES 2160600 T3 ES2160600 T3 ES 2160600T3 ES 93918860 T ES93918860 T ES 93918860T ES 93918860 T ES93918860 T ES 93918860T ES 2160600 T3 ES2160600 T3 ES 2160600T3
Authority
ES
Spain
Prior art keywords
cells
objective
photosensible
animal
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93918860T
Other languages
English (en)
Inventor
Anna M Richter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novelion Therapeutics Inc
Original Assignee
Quadra Logic Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadra Logic Technologies Inc filed Critical Quadra Logic Technologies Inc
Application granted granted Critical
Publication of ES2160600T3 publication Critical patent/ES2160600T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Radiation-Therapy Devices (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

UN METODO QUE DESTRUYE O DAÑA CELULAS OBJETIVO QUE TIENEN UN AGENTE FOTOSENSIBLE ACUMULADO SELECTIVAMENTE. LAS CELULAS OBJETIVOS ESTAN EN LA CORRIENTE SANGUINEA DE UN ANIMAL INTEGRO, CUYA CORRIENTE SANGUINEA Y ANIMAL CONTIENEN ADICIONALMENTE CELULAS DISTINTAS A LAS OBJETIVO. SE APLICA TRANSCUTANEAMENTE RADIACION A AL MENOS UNA PORCION DEL ANIMAL INTEGRO CON UNA INTENSIDAD EFECTIVA PARA DAÑAR O DESTRUIR SELECTIVAMENTE LAS CELULAS OBJETIVO Y PARA DEJAR LAS CELULAS DISTINTAS A LAS OBJETIVO RELATIVAMENTE NO DAÑADAS. LAS CELULAS OBJETIVO INCLUYEN CELULAS DE LEUCEMIA, CELULAS QUE CONTIENEN VIRUS, CELULAS QUE CONTIENEN PARASITO, Y MICROORGANISMOS TALES COMO BACTERIAS, PARASITOS Y VIRUS LIBRES.
ES93918860T 1992-09-21 1993-09-20 Activacion transcutanea in vivo de agentes fotosensibles en la sangre. Expired - Lifetime ES2160600T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94811392A 1992-09-21 1992-09-21

Publications (1)

Publication Number Publication Date
ES2160600T3 true ES2160600T3 (es) 2001-11-16

Family

ID=25487290

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93918860T Expired - Lifetime ES2160600T3 (es) 1992-09-21 1993-09-20 Activacion transcutanea in vivo de agentes fotosensibles en la sangre.

Country Status (21)

Country Link
US (2) US5484803A (es)
EP (1) EP0660712B1 (es)
JP (2) JP3598306B2 (es)
AT (1) ATE201596T1 (es)
AU (1) AU681088B2 (es)
CA (1) CA2144327C (es)
DE (1) DE69330277T2 (es)
DK (1) DK0660712T3 (es)
ES (1) ES2160600T3 (es)
FI (1) FI951295L (es)
GR (1) GR3036479T3 (es)
HU (1) HU220251B (es)
IL (1) IL107035A (es)
NO (1) NO951066L (es)
NZ (1) NZ255302A (es)
PL (1) PL308116A1 (es)
PT (1) PT660712E (es)
SK (1) SK35295A3 (es)
TW (1) TW241204B (es)
WO (1) WO1994006424A1 (es)
ZA (1) ZA936968B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955490A (en) * 1989-07-28 1999-09-21 Queen's University At Kingston Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
US6710066B2 (en) * 1989-07-28 2004-03-23 Queen's University At Kingston Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
US20020058008A1 (en) * 1989-07-28 2002-05-16 Kennedy James C. Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
US5587490A (en) * 1990-04-16 1996-12-24 Credit Managers Association Of California Method of inactivation of viral and bacterial blood contaminants
US5798238A (en) * 1990-04-16 1998-08-25 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants with quinolines as photosensitizer
US20040110819A1 (en) * 1991-10-28 2004-06-10 Queen's University At Kingston Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
PL172480B1 (pl) * 1992-11-20 1997-09-30 Univ British Columbia Kompozycja do niszczenia lub uszkadzania obszaru nowego unaczynienia PL PL
EP0831909B1 (en) * 1995-06-05 2005-01-26 Queen's University at Kingston Use of a protoporphyrin ix precursor in the treatment of dermatophytoses and malaria after photoactivation of said protoporphyrin
US6008211A (en) * 1995-07-27 1999-12-28 Pdt Pharmaceuticals, Inc. Photoactivatable compounds comprising benzochlorin and furocoumarin
EP0881874B1 (en) * 1995-11-06 2003-04-02 New York Blood Center, Inc. Viral inactivation treatment of red blood cells using phthalocyanines and red light
US5895786A (en) 1996-05-08 1999-04-20 New York Blood Center, Inc. Method for treating viral infections
US6159733A (en) * 1996-06-20 2000-12-12 New York Blood Center, Inc. Method for photoinactivating malignant cells
US5922278A (en) † 1996-11-19 1999-07-13 Baxter International Inc. Method and apparatus for inactivating contaminants in biological fluid
US5742380A (en) * 1996-12-31 1998-04-21 Ronn Avigdor M Plasma assay spectrometer
US6010890A (en) * 1997-04-29 2000-01-04 New York Blood Center, Inc. Method for viral inactivation and compositions for use in same
US6103706A (en) * 1997-04-29 2000-08-15 New York Blood Center, Inc. Methods for treating viral infections
US5856566A (en) 1997-09-02 1999-01-05 Dusa Pharmaceuticals, Inc. Sterilized 5-aminolevulinic acid
US6159178A (en) 1998-01-23 2000-12-12 Heartport, Inc. Methods and devices for occluding the ascending aorta and maintaining circulation of oxygenated blood in the patient when the patient's heart is arrested
US6096066A (en) * 1998-09-11 2000-08-01 Light Sciences Limited Partnership Conformal patch for administering light therapy to subcutaneous tumors
US6183773B1 (en) 1999-01-04 2001-02-06 The General Hospital Corporation Targeting of sebaceous follicles as a treatment of sebaceous gland disorders
US6454789B1 (en) 1999-01-15 2002-09-24 Light Science Corporation Patient portable device for photodynamic therapy
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
EP1131099A2 (en) 1999-01-15 2001-09-12 Light Sciences Corporation Noninvasive vascular therapy
ATE234114T1 (de) * 1999-01-15 2003-03-15 Light Sciences Corp Therapeutische zusammensetzungen fur knochenstoffwechselstörungen oder knochenmetastasen enthaltend einen photosensitizer und ein bisphosphonat
US6376483B1 (en) 1999-05-27 2002-04-23 Miravant Pharmaceuticals, Inc. Bacteriochlorins and bacteriopurpurins useful as photoselective compounds for photodynamic therapy and a process for their production
US20030114434A1 (en) * 1999-08-31 2003-06-19 James Chen Extended duration light activated cancer therapy
DE19960705A1 (de) * 1999-12-16 2001-06-21 Laser & Med Tech Gmbh Verfahren und Vorrichtung zur Herstellung eines autologen Immunisierungsimpfstoffes gegen Krebserkrankungen (Tumorvakzine)
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
CA2395567A1 (en) 2000-01-12 2001-07-19 Light Sciences Corporation Novel treatment for eye disease
KR100365151B1 (ko) * 2000-05-08 2003-02-11 김형락 어류 병원성 세균과 바이러스의 감염 예방 및 치료를 위한δ-아미노레불린산의 신규한 용도
DE10034673C1 (de) 2000-07-17 2002-04-25 Medac Klinische Spezialpraep Dermales Applikationssystem für Aminolävulinsäure und seine Verwendung
JP2004506005A (ja) 2000-08-16 2004-02-26 ザ　ジェネラル　ホスピタル　コーポレイション　ディー　ビー　エイ　マサチューセッツ　ジェネラル　ホスピタル 尋常性挫瘡用の局所アミノレブリン酸−光力学的治療
EP2248536A3 (en) 2000-12-14 2010-12-08 The General Hospital Corporation doing business as Massachusetts General Hospital Topical Aminolevulinic acid-photodynamic therapy for acne vulgaris
CA2445898A1 (en) * 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
JP2005502618A (ja) * 2001-06-04 2005-01-27 ザ・ジェネラル・ホスピタル・コーポレイション 光力学的化合物を用いて脆弱なプラークを検出および治療する方法
DE10162712A1 (de) * 2001-12-19 2003-07-17 Blutspendienst Der Landesverba Verfahren zur Inaktivierung von Bakterien und Leukozyten in Blut oder Blutprodukten
CA2473924A1 (en) * 2002-01-23 2003-07-31 Light Sciences Corporation Systems and methods for photodynamic therapy
AU2003248747A1 (en) 2002-06-27 2004-01-19 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
WO2004005289A2 (en) 2002-07-02 2004-01-15 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
US7659301B2 (en) * 2003-04-15 2010-02-09 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
US7220778B2 (en) * 2003-04-15 2007-05-22 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
US20070020272A1 (en) * 2003-04-30 2007-01-25 Tayyaba Hasan Indirectly linked photosensitizer immunoconjugates, processes for the production thereof and methods of use thereof
JP2007500227A (ja) * 2003-05-29 2007-01-11 ミトス・ファーマシューティカルズ・インコーポレーテッド 光増感剤及び音増感剤と関連してのニトロキシドの使用方法
FR2857264A1 (fr) * 2003-07-09 2005-01-14 Maco Pharma Sa Procede d'inactivation photodynamique des pathogenes au moyen d'ala
GB0424833D0 (en) 2004-11-10 2004-12-15 Photocure Asa Method
US8585707B2 (en) 2006-06-07 2013-11-19 Gary S. Rogers Continuous low irradiance photodynamic therapy method
US20080164224A1 (en) * 2007-01-04 2008-07-10 Whirlpool Corporation System for connecting mechnically dissimilar consumer electronic devices to an adaptor or a host
CA2724949A1 (en) 2007-06-27 2008-12-31 The General Hospital Corporation Method and apparatus for optical inhibition of photodynamic therapy
US20090062724A1 (en) * 2007-08-31 2009-03-05 Rixen Chen System and apparatus for sonodynamic therapy
US8835104B2 (en) * 2007-12-20 2014-09-16 Fenwal, Inc. Medium and methods for the storage of platelets
JP2014518547A (ja) 2011-04-07 2014-07-31 フェンウォール、インコーポレイテッド 削減された残存血漿容積を有する血小板濃縮物を提供するための自動化方法とシステムおよびそのような血小板濃縮物のための貯蔵媒体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US4961920A (en) * 1988-12-08 1990-10-09 Luminis Pty, Ltd. Phototherapeutic monovinyl and divinyl ether-linked dimers
US4960408A (en) * 1989-01-10 1990-10-02 Klainer Albert S Treatment methods and vaccines for stimulating an immunological response against retroviruses

Also Published As

Publication number Publication date
WO1994006424A1 (en) 1994-03-31
IL107035A0 (en) 1993-12-28
CA2144327C (en) 2002-08-06
CA2144327A1 (en) 1994-03-31
NO951066L (no) 1995-05-19
AU4940593A (en) 1994-04-12
IL107035A (en) 1998-12-27
JP3598306B2 (ja) 2004-12-08
FI951295A7 (fi) 1995-05-17
JP2001316288A (ja) 2001-11-13
EP0660712B1 (en) 2001-05-30
PL308116A1 (en) 1995-07-24
NZ255302A (en) 2001-04-27
US5736563A (en) 1998-04-07
EP0660712A1 (en) 1995-07-05
TW241204B (es) 1995-02-21
ATE201596T1 (de) 2001-06-15
DK0660712T3 (da) 2001-08-27
SK35295A3 (en) 1996-05-08
GR3036479T3 (en) 2001-11-30
DE69330277T2 (de) 2002-04-18
NO951066D0 (no) 1995-03-20
FI951295L (fi) 1995-05-17
DE69330277D1 (de) 2001-07-05
US5484803A (en) 1996-01-16
JPH08501301A (ja) 1996-02-13
AU681088B2 (en) 1997-08-21
HUT70966A (en) 1995-11-28
PT660712E (pt) 2001-11-30
HU220251B (hu) 2001-11-28
FI951295A0 (fi) 1995-03-20
ZA936968B (en) 1994-04-12

Similar Documents

Publication Publication Date Title
ATE201596T1 (de) Transkutane in-vivo aktivierung von photoempfindlichen mitteln im blut
ES2180792T3 (es) Acidos linoleicos conjugados para atenuar la respuesta alergica.
AR247063A1 (es) Un aparato para el control de insectos.
ES2161210T3 (es) Composiciones anti-patogenamente eficaces que comprenden peptidos liticos y enzimas hidroliticas.
ES2147752T3 (es) Descontaminacion de plaquetas con 8-metoxipsoraleno.
ES2169012T1 (es) Dispositivo medico con superficie porosa para liberacion controlada de farmacos y metodo de fabricarlo.
ATE317894T1 (de) Desinfizierendes waschen empfindlicher textilien mit persäuren
ES2156934T3 (es) Compuestos que presentan una potente actividad de antagonistas del calcio y de antioxidantes y su utilizacion como agentes citoprotectores.
FI960281A0 (fi) Menetelmä tuotteiden sterilisoimiseksi
BR0016189A (pt) Chumaço de algodão hidrófilo destinado aos cuidados da pele e compreendendo duas faces externas diferentes
AR000372A1 (es) Medio de retención y distribución de líquido método de preparación del mismo y producto absorbente que lo contiene
AR029144A1 (es) Composicion cosmetica y/o dermatologica destinada al tratamiento de las fibras queratinicas, en particular de las fibras queratinicas humanas y mas especificamente del cabello humano, procedimientos de tratamiento de las fibras queratinicas, en particular del cabello, con el fin de obtener una defor
AR019309A1 (es) Composicion de tenido para fibras queratinicas con un colorante directo cationico y un polimero sustantivo
ES2147754T3 (es) Inactivacion selectiva de celulas en sangre.
ES2161762T3 (es) Polimeros de ionenos como antihelminticos en animales.
AR026970A1 (es) Una composicion que comprende un agente de fijacion del tenido y proceso para tratar telas
AR004494A1 (es) Una celula util para el tratamiento del dolor, un metodo para producirla, un organo bioartificial de la comprende y un metodo para preparar dicho organobioartificial
AR246159A1 (es) Agente antiparasitario con accion mejorada.
PT768886E (pt) Efeitos de revestimento endotelial e tratamento de desordens vasospasticas
CO5070648A1 (es) Articulo absorbente con propiedades mejoradas de manejo de desechos corporales fluidos viscosos
WO2001089997A3 (en) Means for electrochemical treatment of water
ES2168583T3 (es) Parasitos que infectan macrofagos que expresan un factor que estimula colonias de macrofagos granulociticos.
CO5070608A1 (es) Metodo para aumentar la permeabilidad del tejido corneo humano
ATE414513T1 (de) Verfahren für die photodynamische inaktivierung von pathogenen mit ala
ES2109109T3 (es) Procedimiento de ensayo de materias activas en cabellos depilados.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 660712

Country of ref document: ES